Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932

Published: Tuesday, February 21, 2012
Last Updated: Monday, February 20, 2012
Bookmark and Share
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.

Curis, Inc. and Debiopharm Group have announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932.

Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

“Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm’s pipeline,” said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

Mauvernay continued, “We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932.”

“We have been highly impressed with the depth of Debiopharm’s development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012,” said Dan Passeri, Curis President and Chief Executive Officer.

Passeri continued, “Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm and TCGLS Enter Into an Exclusive Research Agreement
Collaboration to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm.
Tuesday, September 10, 2013
Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement
Agreement for the manufacturing and commercialization of Huperzine-A.
Wednesday, April 10, 2013
Debiopharm and Ascepion Announce an Exclusive License Agreement
Agreement for the development and commercialization of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases.
Tuesday, June 19, 2012
Debiopharm and Aurigene Sign Agreement for the Development and Commercialization of Debio 1142
The Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours.
Wednesday, April 27, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients
Debiopharm Group announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl® (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Thursday, September 25, 2008
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!